Rigaku Launches Fourth Generation Handheld 1064 nm Raman Analyzer for Chemical Threat Analysis at IAFC HAZMAT 2025
WILMINGTON, Mass.--(BUSINESS WIRE)--Rigaku Analytical Devices, a division under Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; President and CEO: Jun Kawakami), announces the launch of its fourth generation 1064 nm Raman analyzers - the Icon series, featuring enhancements in chemical threat analysis for safety and security applications. The first in the series, the Icon-X, will be showcased at The International Hazardous Materials Response Teams Conference (HAZMAT), hosted by the International Association of Fire Chiefs (IAFC), in Baltimore, MD USA from June 13-14, 2025. From June 13 onward, we will begin rolling out global sales.
The Icon-X is the first 1064 nm Raman analyzer to provide standoff chemical analysis allowing users to analyze potentially dangerous substances from a safe distance. This is critical for military, first responders, EOD, and border protection teams who could potentially be exposed to explosive threats, such as improvised explosive devices (IEDs), homemade explosives (HMEs), and chemical threats. This new, optional feature also reduces the need for time-consuming sample collection, while allowing responders to assess hazards without disrupting the scene.
In addition to the new standoff capability, the Icon-X contains an on-board, comprehensive library of chemical warfare agents (CWAs), explosives, narcotics, toxic industrial chemicals, precursors, cutting agents, and more. The Icon-X features a more ergonomic form factor, with improvements in all areas over previous generations, including:
Use of the latest technology for enhanced processing
Illuminated keypad and larger, more responsive touchscreen for easier use
Optional GPS ability to mark critical scan data for fleet management and sensitive site exploitation
Upgraded 13MP camera with LED flash for more clear images
Meets the MIL-STD-810H standard for durability, passing tests for shock, pressure, and extreme temperatures. It also has IP68 certification, making it fully dustproof and waterproof—ideal for tough environments and decontamination use
New accessories to expand applications, such as a ball probe to scan inside a deep container
As criminal networks become more sophisticated with easier access to chemicals and dangerous recipes, the need for first responders to have cutting-edge technology has never been more critical. Based on the success of Rigaku's previous generations of handheld 1064 nm Raman technology, the Icon series provides users with reliable results, allowing them to respond faster, while keeping them safe from exposure. The utilization of 1064 nm Raman technology means users can scan through translucent packaging and identify dirty or mixed substances without fluorescence issues, a common issue for older Raman technology.
'While developing the Icon Series, we considered the years of feedback received from our global network of 1064 nm Raman users and partners,' said Dr. Michael Hargreaves, Vice President of Science & Technology at Rigaku Analytical Devices. 'This allowed us to take a proven, field-accessible technology to the next level, and really expand the capabilities of handheld Raman spectroscopy. '
The Rigaku Icon-X will be demonstrated in booth #314 at the IAFC Hazmat Show in Baltimore, MD USA from June 13-14, 2025.
The Rigaku Icon-X joins the award-winning 1064 nm fleet of Rigaku CQL analyzers and is supported by Rigaku's global sales and distribution channels. For more information on the Icon-X, please visit: www.rigakuanalytical.com.
About the Rigaku Group
Since its establishment in 1951, the engineering professionals of the Rigaku group have been dedicated to benefiting society with leading-edge technologies, notably including its core fields of X-ray and thermal analysis. With a market presence in over 90 countries and some 2,000 employees from 9 global operations, Rigaku is a solution partner in industry and research analysis institutes. Our overseas sales ratio has reached approximately 70% while sustaining an exceptionally high market share in Japan. Together with our customers, we continue to develop and grow. As applications expand from semiconductors, electronic materials, batteries, environment, resources, energy, life science to other high-tech fields, Rigaku realizes innovations 'To Improve Our World by Powering New Perspectives.'
For details, please visit rigaku-holdings.com/english
About Rigaku Analytical Devices
Rigaku Analytical Devices is a pioneer in handheld 1064 nm Raman spectroscopy. Our products are trusted by law enforcement departments, government agencies, and security specialists to identify chemical threats. The pharmaceutical manufacturing sector relies on us for quality control. At Rigaku, we are focused on supporting our clients with our global expertise and developing innovative solutions that perform optimally, mitigate new chemical threats, and are always reliable and cost effective. Our rugged products deliver unparalleled accuracy and support for rapid lab-quality results any time, any place. For more information: http://www.rigakuanalytical.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
8 minutes ago
- Business Wire
Resecurity Expands LATAM Presence Through Strategic Partnership with INFORC in Ecuador
LOS ANGELES & QUITO, Ecuador--(BUSINESS WIRE)-- Resecurity, a U.S.-based cybersecurity and threat intelligence company, is pleased to announce a new strategic partnership with INFORC ECUADOR, a leading Ecuadorian cybersecurity company that specializes in offering cybersecurity solutions and services to organizations across the region. This partnership marks a key development in Resecurity's expansion strategy across Latin America, solidifying its presence in Ecuador and further enhancing the availability of its advanced threat intelligence and cybersecurity solutions to local organizations. Founded in 2005, INFORC ECUADOR® is widely recognized for its expertise in information security compliance, secure software development, incident response (CSIRT), and offensive security testing. As a reseller of Resecurity's cybersecurity solutions, INFORC will help local organizations strengthen their cybersecurity posture by delivering Resecurity's state-of-the-art products, including the Context™ threat intelligence platform, advanced endpoint protection, and fraud prevention solutions. Through this partnership, INFORC will: Offer Resecurity's market-leading cyber threat intelligence and fraud prevention solutions to Ecuadorian enterprises and government entities. Deliver expert services related to Resecurity's platform implementation, training, and support. Collaborate with Resecurity to offer cybersecurity compliance, incident response, and intelligence services tailored to Ecuador's regulatory environment. Provide enhanced threat detection, phishing prevention, malware tracking, and brand abuse protection solutions. "Our partnership with Resecurity is a significant milestone in our mission to deliver cutting-edge cybersecurity solutions to Ecuador," said Ing. Carlos Jumbo, CEO of INFORC. "By reselling Resecurity's solutions, we can offer our clients world-class cyber threat intelligence and risk management capabilities to help them secure their operations and meet compliance requirements." "We are thrilled to partner with INFORC to bring our advanced cybersecurity solutions to Ecuador," said Gene Yoo, CEO of Resecurity."This partnership helps us further extend our presence in Latin America and equips INFORC with the tools and expertise needed to help local organizations defend against increasingly sophisticated cyber threats." The collaboration is poised to address the growing demand for cybersecurity solutions in Ecuador, especially in light of rising cyber threats targeting both public and private sector entities. INFORC's trusted status in the region, combined with Resecurity's innovative technology, will provide Ecuadorian organizations with the advanced tools necessary to proactively manage and mitigate digital risks. With this agreement, Resecurity continues its commitment to building strong relationships with regional partners across Latin America, reinforcing its role as a key player in the cybersecurity space. About Resecurity® Resecurity® is a cybersecurity company that delivers a unified endpoint protection, fraud prevention, risk management, and cyber threat intelligence platform. Known for providing best-of-breed data-driven intelligence solutions, Resecurity's services and platforms focus on early-warning identification of data breaches and comprehensive protection against cybersecurity risks. Founded in 2016, it has been globally recognized as one of the world's most innovative cybersecurity companies with the sole mission of enabling organizations to combat cyber threats regardless of how sophisticated they are. Most recently, by Inc. Magazine, Resecurity was named one of the Top 10 fastest-growing private cybersecurity companies in Los Angeles, California. As a member of InfraGard National Members Alliance (INMA), AFCEA, NDIA, SIA, FS-ISAC, and the American Chamber of Commerce in Saudi Arabia (AmChamKSA), Singapore (AmChamSG), Korea (AmChamKorea), Mexico (AmChamMX), Thailand (AmChamThailand), and UAE (AmChamDubai). To learn more about Resecurity, visit About INFORC ECUADOR® Founded in 2005, INFORC ECUADOR® is a leading Ecuadorian cybersecurity company recognized for its expertise in providing comprehensive cybersecurity services and solutions. With a strong presence in the local market, INFORC specializes in areas such as information security compliance, secure software development, incident response, penetration testing, phishing detection, and cyber intelligence services. The company also offers cybersecurity training, awareness programs, and operates a Computer Security Incident Response Team (CSIRT). INFORC's in-depth knowledge of the Ecuadorian market and its commitment to delivering top-tier security solutions make it a trusted partner for both private and public sector organizations. Learn more at
Business Wire
an hour ago
- Business Wire
Cosmetics Industry Icon Leonard A. Lauder, Chairman Emeritus, The Estée Lauder Companies, Passes Away
NEW YORK--(BUSINESS WIRE)--It is with deep sadness that The Estée Lauder Companies Inc. (NYSE: EL) announces that Chairman Emeritus Leonard A. Lauder passed away on June 14, at the age of 92, surrounded by family. Mr. Lauder was born in 1933 in New York City, the oldest son of Estée and Joseph H. Lauder, the founders of The Estée Lauder Companies. He was a graduate of the Bronx High School of Science, the University of Pennsylvania's Wharton School, and the Officer Candidate School of the United States Navy. Mr. Lauder studied at Columbia University's Graduate School of Business. He served as a lieutenant in the U.S. Navy and as a Navy reservist, for which the U.S. Navy Supply Corps Foundation later recognized him with its Distinguished Alumni Award. He formally joined Estée Lauder in 1958, and for more than six decades, Mr. Lauder was a visionary and an innovator, helping transform the business from a handful of products sold under a single brand in U.S. stores to the multi-brand, global leader in prestige beauty that it is today. 'Throughout his life, my father worked tirelessly to build and transform the beauty industry, pioneering many of the innovations, trends, and best practices that are foundational to the industry today,' said William P. Lauder, son and Chair, Board of Directors, The Estée Lauder Companies. 'He was the most charitable man I have ever known, believing that art and education belonged to everyone, and championing the fight against diseases such as Alzheimer's and breast cancer. Above all, my father was a man who practiced kindness with everyone he met. His impact was enormous. He believed that employees were the heart and soul of our company, and they adored him and moments spent with him. His warmth and thoughtfulness made an imprint on our company, the industry, and, of course, our family. Together with my family, The Estée Lauder Companies, and the countless people he touched, we celebrate his extraordinary life.' Mr. Lauder served as President of The Estée Lauder Companies from 1972 to 1995 and as Chief Executive Officer from 1982 through 1999. He was named Chairman in 1995 and served in that role through June 2009. Throughout his tenure at the company, Mr. Lauder consistently challenged the status quo, developing and implementing innovative sales and marketing programs that revolutionized the beauty industry. He created the company's first research and development laboratory, brought in professional management at every level, and was the driving force behind The Estée Lauder Companies' international expansion, helping to increase the company's sales and profits exponentially. A legendary brand builder, Mr. Lauder led the launch of many brands including Aramis, Clinique, and Lab Series, among others. Until his death, he remained deeply involved in the company's acquisition strategy, including the acquisitions of Aveda, Bobbi Brown, Jo Malone London, La Mer, and M∙A∙C. Speaking for The Estée Lauder Companies, President and Chief Executive Officer Stéphane de La Faverie said, 'Leonard Lauder was beloved by many and will be missed tremendously. To our employees at The Estée Lauder Companies, he was an inspiration and a champion. To the industry, he was an icon and pioneer, earning respect worldwide. His energy and vision helped shape our company and will continue to do so for generations to come. He was a deeply compassionate leader who cared profoundly about every person in the company. I feel privileged to have worked with Leonard, who has been the best mentor I could have dreamt to learn from. He will be remembered by all of us.' During his many years as Chairman Emeritus, Mr. Lauder was closely involved in the business and day-to-day operations of the company and was a constant fixture at The Estée Lauder Companies' global headquarters in New York and at our stores and counters across the globe until the time of his death. Mr. Lauder believed that each of his colleagues was like a member of his family and treated them as such. The values that continue to set the company apart are the values he so strongly believed in and embodied, most notably generosity of spirit and kindness toward all. Perhaps the role Mr. Lauder was most proud of was the unofficial one as The Estée Lauder Companies' 'chief teaching officer.' He believed that a company's wealth is its people and focused on mentoring and fostering growth within the company's diverse talent pool. He believed strongly in the importance of recognition and gratitude and was a tireless advocate for employees. At the onset of the global pandemic in 2020, Mr. Lauder was instrumental in setting up the ELC Cares Employee Relief Fund to support the physical, mental, and emotional well-being of employees and their families. Mr. Lauder was deeply involved in medical research, education, art, foreign policy, and philanthropy, and the marks he made on those worlds were transformational. Mr. Lauder believed passionately in the importance of public access to art and museums, which inspired his philosophy that the primary role of a collector was to conserve, not possess. He was a long-time supporter of the Metropolitan Museum of Art (the Met) and, in 2013, pledged his 78-piece collection of Cubist art to the museum in the largest single philanthropic gift in the Met's history. He later added five major works to that promised gift. In concert with his Cubist collection donation, he helped establish the Leonard A. Lauder Research Center for Modern Art at the Met to support a robust program of fellowships, focused exhibitions, and public lectures. Along with his prominent presence at the Met, he also served as the Whitney Museum of American Art's Chairman Emeritus and a trustee from 1977 to 2011. Throughout his life, he donated works of art and endowed curatorial positions and research departments to numerous institutions. Mr. Lauder was a long-time advocate of cancer research and served as Honorary Chairman of the board of directors at the Breast Cancer Research Foundation, the organization his beloved late-wife, Evelyn H. Lauder, founded in 1993. He also championed the fight against Alzheimer's by co-founding and leading the Alzheimer's Drug Discovery Foundation with his brother, Ronald S. Lauder, which supports cutting-edge drug research. Mr. Lauder remained actively engaged with these organizations until his death, and they were extraordinarily dear to his heart. Remembering his brother, Ronald S. Lauder, Chairman, Clinique Laboratories, LLC at The Estée Lauder Companies, said, 'Leonard was a wonderful brother and a devoted husband, father, grandfather, great-grandfather, uncle, colleague, and friend. But his legacy extends far beyond being the heart of our family. His impact will be felt for generations to come thanks to his tireless philanthropy, advocacy, and creativity in tackling some of the world's greatest challenges. The number of lives he touched and positively impacted across all his endeavors is immeasurable. His passion and generosity have inspired us all, and there are no words to express how much he will be missed.' 'My father was a remarkable man, a leader in business, a devoted philanthropist, and a deeply loving father, grandfather, and great-grandfather,' said Gary M. Lauder, son and Member, Board of Directors, The Estée Lauder Companies. 'His energy, sharp intellect, and generous spirit touched the lives of so many across the world. To me, he was also a constant source of encouragement, wisdom, and love. His legacy is vast, not only in the beauty industry, but in the countless lives improved by his charitable efforts and his passionate commitment to the arts, education, and healthcare. He was not only well-respected and admired, but he was also adored by his employees and colleagues. This affection stands out for me. While we mourn his passing, we also celebrate his extraordinary life, his lasting contributions, and the values he instilled in all of us: integrity, curiosity, and the importance of giving back. He will be missed more than words can express.' Mr. Lauder believed in the value of education and supported a variety of academic institutions. He was an emeritus trustee of the University of Pennsylvania and a founding member of the board of governors of its Joseph H. Lauder Institute of Management and International Studies, along with his brother, Ronald. His passion for education continued into the public space, having supported several schools in the New York area and receiving the honor of being an inductee into the Bronx High School of Science Hall of Fame in 2017. When the pandemic in 2020 magnified the nation's acute shortage of quality primary care in underserved communities, Mr. Lauder worked with the University of Pennsylvania to create a tuition-free program to educate nurse practitioners. His donation of $125 million, the largest gift ever to an American nursing school, made possible the Leonard A. Lauder Community Care Nurse Practitioner Program at the University of Pennsylvania. Mr. Lauder worked throughout his life to promote dialogue among governments, political and non-governmental organizations, and the public and private sectors, believing that this interdisciplinary dialogue is crucial to progress. He served as a member of the Council on Foreign Relations and as Chairman Emeritus and a lifetime trustee on the board of directors at the Aspen Institute. He felt that public service was a person's duty and, in addition to his time in the U.S. Navy, later served on the Advisory Committee for Trade Negotiations under President Ronald Reagan from 1983–1987. Throughout his lifetime, Mr. Lauder was honored with a myriad of awards, including the 'Lone Sailor' Award given by the U.S. Navy Supply Corps Foundation, the Légion d'Honneur given by the government of France, the Women's Leadership Award given by the Lincoln Center Corporate Fund Women's Leadership Council, and the Palazzo Strozzi Renaissance Man of the Year Award. In 2020, he was inducted into the Retail Hall of Fame by the World Retail Congress. The Lauder family received the esteemed 2011 Carnegie Medal of Philanthropy in recognition of its long-standing commitment to philanthropy and public service. In 2014, Mr. Lauder was named a Living Landmark by the New York Landmarks Conservancy. Mr. Lauder and Ms. Glickman Lauder also received the Gordon Parks Foundation Patron of the Arts Award in 2016. Mr. Lauder shared many of the lessons he learned in business and life in his memoir, The Company I Keep: My Life in Beauty, published to great acclaim in 2020. He was married to Evelyn H. Lauder, Senior Corporate Vice President at The Estée Lauder Companies and the Founder of the Breast Cancer Research Foundation, from 1959 until she passed away in 2011. On January 1, 2015, Mr. Lauder married Judy Glickman Lauder, a philanthropist and internationally recognized photographer whose work is represented in more than 300 public and private collections, including the J. Paul Getty Museum, the Whitney Museum of Art, the Metropolitan Museum of Art, and the United States Holocaust Museum. Mr. Lauder considered himself lucky in love and believed that lightning really could strike twice. From the beginning, he was devoted to family. He loved his parents and adored his brother, Ronald, and the family Ronald built with Jo Carole. His nieces and their families held a special place in his heart. Mr. Lauder was grateful to his wife, Judy, for widening his family circle and cherished his stepchildren and their families. But mostly, he was extraordinarily proud of both of his sons, their families, and his grandchildren and great-grandchildren. He loved them so dearly. Mr. Lauder was a true visionary, fearless leader, and cherished friend to so many. He was the beacon of our company and the north star of an entire industry. The world is a better place because Leonard Lauder was in it. The Estée Lauder Companies extends our deepest sympathies to the entire Lauder family during this exceedingly difficult time. Mr. Lauder is survived by his wife, Judy Glickman Lauder; his son William P. Lauder; his son Gary M. Lauder and wife, Laura Lauder; five grandchildren, Rachel, Danielle, Djuna-Bear, Joshua, Eliana, two great-grandchildren, many stepchildren and step grandchildren, as well as his brother, Ronald S. Lauder, and wife, Jo Carole Lauder, and their daughters, Aerin Lauder and Jane Lauder. A private service will be held for friends and family. For those who wish, in lieu of flowers, memorial donations may be made to the Breast Cancer Research Foundation and the Alzheimer's Drug Discovery Foundation. The Estée Lauder Companies Inc. (ELC) is one of the world's leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The company's products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, the DECIEM family of brands, including The Ordinary and NIOD, and BALMAIN Beauty.
Business Wire
10 hours ago
- Business Wire
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte's monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofibrosis (MF) and essential thrombocythemia (ET). Under the terms of the Master Collaboration Agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated using the next-generation sequencing (NGS) technology and the Illumina NextSeq 550Dx platform as part of QIAGEN's partnership with Illumina (NASDAQ: ILMN) to leverage its NGS diagnostic platforms for patient testing by laboratories worldwide. QIAGEN will support regulatory submission processes and market access activities across the United States, European Union and Asia-Pacific regions. Myeloproliferative neoplasms are a group of diseases representing about 40% of hematological malignancies, characterized by chronic accumulation of different mature blood cell types in blood. Identifying genomic aberrations in clinically relevant biomarkers like CALR are shown to be key, especially in MPNs. Incyte is at the forefront of developing novel therapies, including INCA033989 for patients with mutCALR ET or MF, that target only malignant cells, sparing normal cells. The use of companion diagnostics helps guide clinicians in making treatment decisions that can lead to better patient outcomes. 'Following our presentation of positive, late-breaking data from our first-in-class mutCALR-targeted antibody at EHA, we are excited to announce this partnership with QIAGEN, which will facilitate CALR testing for patients with MPNs on a global basis. The development of companion diagnostics for mutCALR, coupled with the potential for new medicines to selectively target disease-initiating cells, is a critical step toward changing the course of disease in patients with ET and MF,' said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. 'As a partner, QIAGEN has the proven expertise in companion diagnostics development and approvals needed to support our ongoing work and commitment to transforming the treatment of patients with CALR-mutant MPNs.' 'Together with Incyte we are building a multimodal companion diagnostic using a powerful technology like next-generation sequencing to facilitate highly accurate testing for several blood cancer genes at once,' said Jonathan Arnold, Vice President and Head of Partnering for Precision Diagnostics at QIAGEN. 'This new partnership strengthens our role in offering companion diagnostics for the growing number of biomarkers being discovered in onco-hematology and maximizing the clinical utility of the diagnostic for payor and patient benefit, thus supporting the work of innovative, science-driven companies like Incyte to improve patient outcomes.' About Mutations in Calreticulin (mutCALR) Calreticulin (CALR) is a protein involved in the regulation of cellular calcium levels and normal protein production. Somatic, or non-inherited, DNA mutations in the CALR gene (mutCALR) can result in abnormal protein function and lead to the development of myeloproliferative neoplasms (MPNs), i a closely related group of clonal blood cancers in which the bone marrow functions abnormally, overproducing blood cells. ii,iii Among the two types of MPNs, essential thrombocythemia (ET) and myelofibrosis (MF), mutCALR drives 25-35% of all cases. i,ii About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit QIAGEN is a pioneer in precision medicine and the leader in collaborating with pharmaceutical and biotechnology companies to develop companion diagnostics, having more than 30 master collaboration agreements with global pharmaceutical and biotechnology companies to develop and commercialize diagnostic tests. QIAGEN's offering to these companies encompasses technologies ranging from polymerase chain reaction (PCR), near-patient testing and digital PCR (dPCR) to next-generation sequencing (NGS), and sample types from liquid biopsy to tissue. It also spans disease areas from cancer to non-oncology diseases such as neurodegenerative, inflammatory, and metabolic diseases – including 16 FDA-approved PCR-based companion diagnostics. For more information about QIAGEN's efforts in precision medicine please visit About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For additional information on Incyte, please visit or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube. QIAGEN Forward-Looking Statement Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the 'Risk Factors' contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission. Incyte Forward-Looking Statements Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the potential for Incyte's mut-CALR targeted antibody (INCA033989) to provide a potential treatment option for patients with ET or MF, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on Incyte's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA, EMA, and other regulatory authorities; the efficacy or safety of Incyte and its partners' products; the acceptance of Incyte and its partners' products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended March 31, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements. Source: QIAGEN N.V. Category: Precision Medicine
